top of page
Revolutionizing cancer treatment through next-generation immunotherapies
General
Medical
NEWS
04/01/2026
We entered into a research collaboration with Institute of Science Tokyo (Prof. Hideya Yuasa, School of Life Science and Technology). Research on antitumor compounds via drug repositioning will commence.
03/04/2025
We have received an assignment of a patent for the treatment of refractory cancer (pancreatic cancer, etc.) with three existing pharmaceuticals. The results of an investigator-initiated clinical trial in which two (Nivolumab + Metformin) of the three drugs described in the patent were administered have showed survival of more than 7 years in a patient among advanced pancreatic cancer （Sato R, Hotta K, Kubo T, et al. (February 14, 2025) Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Cureus 17(2). We are going to license the treatment method using the three-drug administration described in the patent to medical institutions from now on.
02/14/2025
Our headquater has moved with business expansion.
12/19/2024
Interview with CEO Yasuyuki Ishii about Japanese cedar pollen allergy was puplished in Jomo newspaper.
01/11/2024
Our president and CEO, Yasuyuki Ishii, spoke at 20th Japanese society of CART Meeting on Dec. 9th, 2023.
bottom of page
